

**EDORAS INVESTMENT HOLDINGS PTE. LTD.**  
(the "**Company**")  
(Company Registration No. 202237475G)  
(Incorporated in the Republic of Singapore)

**April 7, 2026**

To  
**BSE Limited**  
P.J. Towers, Dalal Street,  
Mumbai – 400 001  
*Scrip Code: 544647*  
**Mail Id: corp.relations@bseindia.com**

To  
**National Stock Exchange of India Limited**  
5<sup>th</sup> Floor, Exchange Plaza, Bandra (E),  
Mumbai – 400 051  
*Scrip Symbol: NEPHROPLUS*  
**Mail id: takeover@nse.co.in**

**Sub: Annual Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

Dear Sir/Ma'am,

We, **Edoras Investment Holdings Pte. Ltd**, being a promoter of Nephrocare Health Services Limited ("**Target Company**"), together with persons acting in concert, hereby confirm and declare that, in terms of Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, no encumbrance has been created, directly or indirectly, on the shares of the Target Company during the financial year ended March 31, 2026 other than those already disclosed.

Please take this disclosure on record and acknowledge receipt.

Thanking you.

Yours faithfully,  
**For Edoras Investment Holdings Pte. Ltd**



**Authorized Signatory**

CC:

**a. The Audit Committee**

**b. The Company Secretary and Compliance Officer**

Nephrocare Health Services Limited

*(Formerly Known as Nephrocare Health Services Private Limited)*

5th Floor, D Block, ilabs Centre, Plot 18,

Software, Units Layout, Survey No. 64,

Madhapur, Hyderabad – 500081, Telangana

**Mail id: [cs@nephroplus.com](mailto:cs@nephroplus.com) , [auditcommittee@nephroplus.com](mailto:auditcommittee@nephroplus.com)**